Sermorelin has human evidence showing that it can stimulate the growth-hormone pathway in defined clinical settings. That does not establish general anti-ageing, fat-loss, muscle-building or longevity benefits in healthy adults.
Still uncertain: General anti-ageing, body-composition, performance or longevity benefits in otherwise healthy adults.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
GHRH(1-29) peptide analogue
Entity type
Peptide analogue / modified peptide
Research focus
Growth-hormone diagnostic/deficiency research
Human evidence
Native GHRH(1-29)/sermorelin has genuine human endocrine and diagnostic evidence. In a tiny 6-week study of older men, nightly GHRH increased nocturnal GH but did not significantly improve IGF-I or DEXA body composition.
Regulatory status
Historical FDA marketing approval existed for Geref (sermorelin acetate); this does not confer approval on generic research-market sermorelin.
Main limitations
General anti-ageing, fat-loss, muscle-building or longevity efficacy in otherwise healthy adults.
Safety
GH-axis adverse effects and contraindications are context-specific; unregulated products add purity/identity uncertainty.
Evidence reviewed
2026-09-18
i
Native GHRH(1-29)/sermorelin has genuine human endocrine and diagnostic evidence. In a tiny 6-week study of older men, nightly GHRH increased nocturnal GH but did not significantly improve IGF-I or DEXA body composition.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
1997 · Randomized placebo-controlled clinical physiology study · n=11
Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.
GH-axis adverse effects and contraindications are context-specific; unregulated products add purity/identity uncertainty.
Historical clinical use provides more human exposure than most research peptides, but modern anti-ageing/body-composition use is not the same indication.
Technical details
Mechanism / biologyStimulates pituitary GHRH receptors to release endogenous GH.
Route / formulation boundaryCurrent authorization and product quality must be checked by jurisdiction/product.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceHuman pharmacology dosing verified. A small endocrine study tested IV GHRH(1-29)-NH2/sermorelin at 0.1 and 1.0 micrograms/kg as pulsed challenge doses. This is pharmacology evidence, not a routine self-use regimen.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
2outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
